Seroreactivity to Human Papillomavirus (HPV) Types 16, 18, or 31 and Risk of Subsequent HPV Infection

Results from a Population-Based Study in Costa Rica

Raphael P. Viscidi, Mark Schiffman, Allan Hildesheim, Rolando Herrero, Philip E. Castle, Maria C. Bratti, Ana Cecilia Rodriguez, Mark E. Sherman, Sophia Wang, Barbara Clayman, Robert D. Burk

Research output: Contribution to journalArticle

159 Citations (Scopus)

Abstract

Whether antibodies to human papillomavirus (HPV) capsids, elicited by natural infection, are protective is unknown. This question was addressed in a population-based cohort of 7046 women in Costa Rica by examining the association between baseline seroreactivity to HPV-16, HPV-18, or HPV-31 virus-like particles and the risk of subsequent HPV infection at a follow-up visit 5-7 years after enrollment. Seropositivity to HPV-16, HPV-18, or HPV-31 was not associated with a statistically significant decreased risk of infection with the homologous HPV type [relative risk (RR) and [95% confidence interval (CI)], 0.74 (0.45-1.2), 1.5 (0.83-2.7), and 0.94 (0.48-1.8), respectively]. Seropositivity to HPV-16 or HPV-31 was not associated with a decreased risk of infection with HPV-16 or its genetically related types [RR (95% CI), 0.82 (0.61-1.1) and 0.93 (0.68-1.2), respectively]. Seropositivity to HPV-18 was not associated with a decreased risk of infection with HPV-18 or its genetically related types (RR 1.3; 95% CI 1.0-1.8). Thus, we did not observe immunity, although a protective effect from natural infection cannot be excluded because of the limits of available assays and study designs.

Original languageEnglish (US)
Pages (from-to)324-327
Number of pages4
JournalCancer Epidemiology Biomarkers and Prevention
Volume13
Issue number2
DOIs
StatePublished - Feb 2004

Fingerprint

Human papillomavirus 31
Costa Rica
Papillomavirus Infections
Human papillomavirus 16
Human papillomavirus 18
Population
Infection
Confidence Intervals
Papillomaviridae
Capsid
Virion
Immunity
Antibodies

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Seroreactivity to Human Papillomavirus (HPV) Types 16, 18, or 31 and Risk of Subsequent HPV Infection : Results from a Population-Based Study in Costa Rica. / Viscidi, Raphael P.; Schiffman, Mark; Hildesheim, Allan; Herrero, Rolando; Castle, Philip E.; Bratti, Maria C.; Rodriguez, Ana Cecilia; Sherman, Mark E.; Wang, Sophia; Clayman, Barbara; Burk, Robert D.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 13, No. 2, 02.2004, p. 324-327.

Research output: Contribution to journalArticle

Viscidi, Raphael P. ; Schiffman, Mark ; Hildesheim, Allan ; Herrero, Rolando ; Castle, Philip E. ; Bratti, Maria C. ; Rodriguez, Ana Cecilia ; Sherman, Mark E. ; Wang, Sophia ; Clayman, Barbara ; Burk, Robert D. / Seroreactivity to Human Papillomavirus (HPV) Types 16, 18, or 31 and Risk of Subsequent HPV Infection : Results from a Population-Based Study in Costa Rica. In: Cancer Epidemiology Biomarkers and Prevention. 2004 ; Vol. 13, No. 2. pp. 324-327.
@article{50d5e7049f4d487b8f1771c52e2007fa,
title = "Seroreactivity to Human Papillomavirus (HPV) Types 16, 18, or 31 and Risk of Subsequent HPV Infection: Results from a Population-Based Study in Costa Rica",
abstract = "Whether antibodies to human papillomavirus (HPV) capsids, elicited by natural infection, are protective is unknown. This question was addressed in a population-based cohort of 7046 women in Costa Rica by examining the association between baseline seroreactivity to HPV-16, HPV-18, or HPV-31 virus-like particles and the risk of subsequent HPV infection at a follow-up visit 5-7 years after enrollment. Seropositivity to HPV-16, HPV-18, or HPV-31 was not associated with a statistically significant decreased risk of infection with the homologous HPV type [relative risk (RR) and [95{\%} confidence interval (CI)], 0.74 (0.45-1.2), 1.5 (0.83-2.7), and 0.94 (0.48-1.8), respectively]. Seropositivity to HPV-16 or HPV-31 was not associated with a decreased risk of infection with HPV-16 or its genetically related types [RR (95{\%} CI), 0.82 (0.61-1.1) and 0.93 (0.68-1.2), respectively]. Seropositivity to HPV-18 was not associated with a decreased risk of infection with HPV-18 or its genetically related types (RR 1.3; 95{\%} CI 1.0-1.8). Thus, we did not observe immunity, although a protective effect from natural infection cannot be excluded because of the limits of available assays and study designs.",
author = "Viscidi, {Raphael P.} and Mark Schiffman and Allan Hildesheim and Rolando Herrero and Castle, {Philip E.} and Bratti, {Maria C.} and Rodriguez, {Ana Cecilia} and Sherman, {Mark E.} and Sophia Wang and Barbara Clayman and Burk, {Robert D.}",
year = "2004",
month = "2",
doi = "10.1158/1055-9965.EPI-03-0166",
language = "English (US)",
volume = "13",
pages = "324--327",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Seroreactivity to Human Papillomavirus (HPV) Types 16, 18, or 31 and Risk of Subsequent HPV Infection

T2 - Results from a Population-Based Study in Costa Rica

AU - Viscidi, Raphael P.

AU - Schiffman, Mark

AU - Hildesheim, Allan

AU - Herrero, Rolando

AU - Castle, Philip E.

AU - Bratti, Maria C.

AU - Rodriguez, Ana Cecilia

AU - Sherman, Mark E.

AU - Wang, Sophia

AU - Clayman, Barbara

AU - Burk, Robert D.

PY - 2004/2

Y1 - 2004/2

N2 - Whether antibodies to human papillomavirus (HPV) capsids, elicited by natural infection, are protective is unknown. This question was addressed in a population-based cohort of 7046 women in Costa Rica by examining the association between baseline seroreactivity to HPV-16, HPV-18, or HPV-31 virus-like particles and the risk of subsequent HPV infection at a follow-up visit 5-7 years after enrollment. Seropositivity to HPV-16, HPV-18, or HPV-31 was not associated with a statistically significant decreased risk of infection with the homologous HPV type [relative risk (RR) and [95% confidence interval (CI)], 0.74 (0.45-1.2), 1.5 (0.83-2.7), and 0.94 (0.48-1.8), respectively]. Seropositivity to HPV-16 or HPV-31 was not associated with a decreased risk of infection with HPV-16 or its genetically related types [RR (95% CI), 0.82 (0.61-1.1) and 0.93 (0.68-1.2), respectively]. Seropositivity to HPV-18 was not associated with a decreased risk of infection with HPV-18 or its genetically related types (RR 1.3; 95% CI 1.0-1.8). Thus, we did not observe immunity, although a protective effect from natural infection cannot be excluded because of the limits of available assays and study designs.

AB - Whether antibodies to human papillomavirus (HPV) capsids, elicited by natural infection, are protective is unknown. This question was addressed in a population-based cohort of 7046 women in Costa Rica by examining the association between baseline seroreactivity to HPV-16, HPV-18, or HPV-31 virus-like particles and the risk of subsequent HPV infection at a follow-up visit 5-7 years after enrollment. Seropositivity to HPV-16, HPV-18, or HPV-31 was not associated with a statistically significant decreased risk of infection with the homologous HPV type [relative risk (RR) and [95% confidence interval (CI)], 0.74 (0.45-1.2), 1.5 (0.83-2.7), and 0.94 (0.48-1.8), respectively]. Seropositivity to HPV-16 or HPV-31 was not associated with a decreased risk of infection with HPV-16 or its genetically related types [RR (95% CI), 0.82 (0.61-1.1) and 0.93 (0.68-1.2), respectively]. Seropositivity to HPV-18 was not associated with a decreased risk of infection with HPV-18 or its genetically related types (RR 1.3; 95% CI 1.0-1.8). Thus, we did not observe immunity, although a protective effect from natural infection cannot be excluded because of the limits of available assays and study designs.

UR - http://www.scopus.com/inward/record.url?scp=10744233080&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744233080&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-03-0166

DO - 10.1158/1055-9965.EPI-03-0166

M3 - Article

VL - 13

SP - 324

EP - 327

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 2

ER -